Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17518249 | 0.87 | KDM4E (0.40) | KDM4EALDH1A1GAALMNATSHR | |
| SCHEMBL17518389 | 0.82 | KDM4E (0.42) | KDM4EALDH1A1GAAUSP2HSD17B10 | |
| SCHEMBL17087400 | 0.77 | KDM4E (0.46) | KDM4EALDH1A1GAAUSP2LMNA | |
| SCHEMBL17087501 | 0.76 | KDM4E (0.35) | KDM4EALDH1A1GAALMNAL3MBTL1 | |
| SCHEMBL17518390 | 0.75 | GAA (0.48) | KDM4EALDH1A1GAALMNATSHR | |
| SCHEMBL17518331 | 0.74 | GAA (0.47) | KDM4EALDH1A1GAALMNATSHR | |
| SCHEMBL17518320 | 0.73 | KDM4E (0.41) | KDM4EALDH1A1GAALMNATSHR | |
| SCHEMBL17518251 | 0.73 | GAA (0.46) | KDM4EALDH1A1GAALMNATSHR | |
| SCHEMBL13223660 | 0.72 | ALDH1A1 (0.40) | KDM4EALDH1A1USP2HSD17B10LMNA | |
| SCHEMBL17920045 | 0.71 | GRIK1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266927-B2 | Cyclosporin A analogs | ALLERGAN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160039880-A1 | CYCLOSPORIN A ANALOGS | ALLERGAN, INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039880-A1 | CYCLOSPORIN A ANALOGS | TSLP, CHP1, PPP3R1 | KDM4E 4374/4885ALDH1A1 3905/4885GAA 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.